New cell therapy combo targets tough stomach cancers
NCT ID NCT07298200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for advanced gastric cancer that has not responded to standard therapies. It combines a special vaccine made from the patient's own tumor markers (neoantigens) with immune cells trained to attack the cancer. The main goals are to see if the treatment is safe and whether it can shrink tumors or help patients live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Acupuncture with a jolt: could needles shield nerves from chemo?
- Real-World check: does adding nivolumab to chemo help stomach cancer patients?
- Fasting during immunotherapy: a new way to boost treatment?
- New drug combo shows promise for tough stomach cancers
- New injection could spare cancer patients from repeated belly drains
- Cancer combo trial halted early: what we learned